BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
Revenue $401,000, a 175% increase year-over-year.
Loss from Operations $11.6 million, a 24% improvement from a loss of $15.2 million in 2023.
Net Loss $9 million, or $1.16 per share, a 14% improvement from a net loss of $10.4 million, or $2.47 per share, in 2023.
Cash Used in Operating Activities $8.2 million.
Cash, Cash Equivalents and Marketable Securities $10.7 million, with no outstanding debt.
Trade with 70% Backtested Accuracy
Analyst Views on BRTX
No data
About BRTX
About the author
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
- FDA Approval Milestone: Novo Nordisk's once-daily Wegovy obesity pill received FDA approval, leading to a 9.48% increase in after-hours trading to $52.66, marking a significant advancement in obesity treatment that is expected to drive sales growth and enhance market competitiveness.
- Cardiovascular Risk Reduction: Wegovy is not only indicated for weight loss but also approved to reduce the risk of major cardiovascular events in obese patients, which will likely attract more patients with related conditions, thereby expanding the potential market.
- Rising Investor Interest: Despite no new updates, Neumora Therapeutics and BioRestorative Therapies saw increases of 16.02% and 6.90% respectively, indicating broad investor interest and optimism in the biotech sector, which may fuel a wave of investment across the industry.
- Clinical Trial Progress: IDEAYA Biosciences announced full enrollment of 435 patients in its Phase 2/3 trial, with progression-free survival data expected in Q1 2026, potentially paving the way for accelerated approval in the U.S. and further solidifying the company's position in cancer treatment.
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.
Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.
Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.
Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.
